Currently, Nubeqa is approved by the U.S. Food and Drug Administration (FDA) to treat mHSPC, but only in combination with docetaxel chemotherapy. “At the time of initial diagnosis, if a man has ...

The FDA has approved Johnson & Johnson’s prostate cancer ... Pfizer/Astellas with Xtandi (enzalutamide), Bayer/Orion’s Nubeqa (darolutamide), and Takeda’s orteronel. Erleada is a successor ...

Bayer has won a key FDA approval to extend the use of its prostate cancer therapy Nubeqa, as it tries to claim market share from rival drugs and fulfil its aim of building the drug into a €3 ...